Prenyl Synthase Inhibitors: Novel Anti-Infective Agents
异戊二烯合酶抑制剂:新型抗感染剂
基本信息
- 批准号:8532682
- 负责人:
- 金额:$ 33.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-06-01 至 2014-09-09
- 项目状态:已结题
- 来源:
- 关键词:African TrypanosomiasisAlkanesulfonatesAlkynesAmino AcidsAnabolismAnti-Infective AgentsAntimalarialsBacteriaBindingBiological AssayCarotenoidsCatabolismCatalysisCellsChemicalsCollaborationsCombined Modality TherapyCommunicable DiseasesComputing MethodologiesConfocal MicroscopyCrystallographyDevelopmentDiphosphatesDrug TargetingDrug resistanceElectron Nuclear Double ResonanceEnzyme InhibitionEnzymesEpoxy CompoundsErythrocytesGeranyltranstransferaseGrantGrowth InhibitorsHemoglobinHumanIn SituInvestigationLeadMalariaMethodsMonobactamsOrganometallic ChemistryOxidoreductaseParasitesPathway interactionsPharmaceutical PreparationsPhysical condensationPlasmodiumPlasmodium falciparumProteinsProtozoaQuantitative Structure-Activity RelationshipQuinonesReactionReactive Oxygen SpeciesReportingResearchRoentgen RaysRouteSeriesSite-Directed MutagenesisStagingStaphylococcus aureusStructureTestingTropical DiseaseWorkanalogbasecarboxylatechemical synthesiscomputational chemistrydesignenzyme biosynthesisenzyme mechanismfosmidomycingeranylgeranyl diphosphatehemozoinhexokinasehigh throughput screeningin vivoinhibitor/antagonistinorganic phosphateinsightinterestisopentenyl pyrophosphateisoprenoidkillingsmethicillin resistant Staphylococcus aureusnovelnovel strategiespathogenphytoeneprenylpublic health relevancequantumundecaprenyl pyrophosphate synthetase
项目摘要
DESCRIPTION (provided by applicant): The objective of this research is to use a combination of EPR, ENDOR, NMR, X-ray crystallographic, synthetic and computational methods to investigate the structure, function, and inhibition of isoprenoid biosynthesis enzymes of interest as drug targets for treating, primarily, tropical diseases. In Aim 1, we will investigate GcpE, an enzyme involved in isoprenoid biosynthesis in malaria parasites. We hypothesize that its mechanism of action involves unusual metallacycles and that similar metallacycles form with novel alkyne inhibitors. GcpE is an excellent target for the development of novel anti-infectives since it is essential for pathogen survival, is not found in humans, and we have now identified novel inhibitors. In Aim 2 we will carry out a similar series of investigations of the following enzyme (from P. falciparum) in the pathway, LytB, and we hypothesize that because of similarities in their mechanism of action, LytB inhibitors will also inhibit GcpE leading, in cells, to synergistic activity. The third Aim is to develop novel anti-malarials that function by blocking carotenoid and quinone biosynthesis. Carotenoids act to remove reactive oxygen species (ROS, from hemoglobin catabolism) and we hypothesize that carotenoid (and quinone) biosynthesis inhibitors will synergize with current anti-malarials (that enhance ROS formation), reducing drug resistance. The final Aim involves investigation of three other high-value targets: in trypanosomatid parasites, farnesyl diphosphate synthase and hexokinase, in bacteria, undecaprenyl diphosphate synthase. All are essential for survival and sub-micromolar leads have already been identified by us. If successful, the work will provide many new insights into enzyme mechanisms, as well as new drug leads for many global infectious diseases.
PUBLIC HEALTH RELEVANCE: This project is aimed at developing new leads for treating infectious diseases, primarily malaria. Focus will be on developing inhibitors for three unique targets in malaria parasites, and on the use of novel drugs against sleeping sickness.
描述(由申请人提供):本研究的目的是使用EPR, ENDOR, NMR, x射线晶体学,合成和计算方法的组合来研究感兴趣的类异戊二烯生物合成酶的结构,功能和抑制作用,作为治疗热带疾病的药物靶点。在Aim 1中,我们将研究GcpE,一种在疟疾寄生虫中参与类异戊二烯生物合成的酶。我们假设其作用机制涉及不寻常的金属环,并且与新型炔抑制剂形成类似的金属环。GcpE是开发新型抗感染药物的一个极好的靶点,因为它对病原体的生存至关重要,在人类中没有发现,我们现在已经确定了新的抑制剂。在Aim 2中,我们将对途径中的以下酶(来自恶性疟原虫)LytB进行类似的一系列研究,我们假设由于它们的作用机制相似,LytB抑制剂也会抑制GcpE,从而在细胞中产生协同活性。第三个目标是开发通过阻断类胡萝卜素和醌生物合成而起作用的新型抗疟疾药物。类胡萝卜素的作用是去除血红蛋白分解代谢中的活性氧(ROS),我们假设类胡萝卜素(和醌)生物合成抑制剂将与目前的抗疟疾药物协同作用(增强ROS的形成),减少耐药性。最后的目标包括调查其他三个高价值的目标:在锥虫寄生虫中,法尼酯二磷酸合成酶和己糖激酶,在细菌中,十一烯丙烯酯二磷酸合成酶。这些都是生存所必需的,亚微磨牙引线已经被我们发现了。如果成功,这项工作将为酶的机制提供许多新的见解,并为许多全球性传染病提供新的药物线索。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eric Oldfield其他文献
Eric Oldfield的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eric Oldfield', 18)}}的其他基金
Next generation bisphosphonates for chemo- and immuno-therapy
用于化疗和免疫治疗的下一代双膦酸盐
- 批准号:
8444316 - 财政年份:2011
- 资助金额:
$ 33.53万 - 项目类别:
Next generation bisphosphonates for chemo- and immuno-therapy
用于化疗和免疫治疗的下一代双膦酸盐
- 批准号:
8627146 - 财政年份:2011
- 资助金额:
$ 33.53万 - 项目类别:
Next generation bisphosphonates for chemo- and immuno-therapy
用于化疗和免疫治疗的下一代双膦酸盐
- 批准号:
8825340 - 财政年份:2011
- 资助金额:
$ 33.53万 - 项目类别:
Next generation bisphosphonates for chemo- and immuno-therapy
用于化疗和免疫治疗的下一代双膦酸盐
- 批准号:
8085202 - 财政年份:2011
- 资助金额:
$ 33.53万 - 项目类别:
Prenyldiphosphate Synthase Inhibitors: Novel Anti-Infective Agents
异戊二烯二磷酸合酶抑制剂:新型抗感染剂
- 批准号:
7686803 - 财政年份:2002
- 资助金额:
$ 33.53万 - 项目类别:
Prenyl Synthase Inhibitors: Novel Anti-Infective Agents
异戊二烯合酶抑制剂:新型抗感染剂
- 批准号:
7984564 - 财政年份:2002
- 资助金额:
$ 33.53万 - 项目类别: